Allogeneic transplantation for high-risk chronic lymphocytic leukemia—a summary of a 16-year experience

In the pathway inhibitor era, the number of allogeneic stem cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL) continues to decrease and this approach should be offered only after careful risk-benefit assessment. Nevertheless, ASCT still remains only curative therapeutic modality for...

Descripción completa

Detalles Bibliográficos
Autores principales: Helbig, Grzegorz, Spałek, Adrianna, Wieczorkiewicz-Kabut, Agata, Markiewicz, Mirosław, Kopera, Małgorzata, Zielińska, Patrycja, Woźniczka, Krzysztof, Kopińska, Anna, Grygoruk-Wiśniowska, Iwona, Koclęga, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511342/
https://www.ncbi.nlm.nih.gov/pubmed/30919074
http://dx.doi.org/10.1007/s00277-019-03679-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511342/
https://www.ncbi.nlm.nih.gov/pubmed/30919074
http://dx.doi.org/10.1007/s00277-019-03679-x

Ejemplares similares